Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ)
CNY 4.19
(-0.48%)
CNY 4.19
(-0.48%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 802.05 Million | 590.79 Million | 457.97 Million | 742.11 Million | 886.32 Million | -218.56 Million |
| Net Income | 287.23 Million | 268.41 Million | 373.95 Million | 220.57 Million | 263.72 Million | -1.28 Billion |
| Depreciation & Amortization | 255.82 Million | 243.54 Million | 247.33 Million | 231.64 Million | 238.38 Million | 214.87 Million |
| Deferred income taxes | -11.04 Million | -6.78 Million | -9.1 Million | 6.41 Million | -9.58 Million | -7.81 Million |
| Stock-based compensation | - | 31.47 Million | 6 Million | -6.41 Million | 9.58 Million | - |
| Change in working capital | 94.05 Million | -117.13 Million | -338.61 Million | 74.84 Million | 151.69 Million | -897.54 Million |
| Other non-cash items | 593.57 Million | 171.27 Million | 178.4 Million | 215.04 Million | 232.52 Million | 1.74 Billion |
| Investing Cash Flow | 39.8 Million | -118.02 Million | -744.34 Million | 407.99 Million | -253.31 Million | -216.29 Million |
| Investments in PPE | -135.78 Million | -158.78 Million | -253.76 Million | -138.08 Million | -207.53 Million | -263.51 Million |
| Acquisitions | 172.51 Million | 1.6 Million | -295.48 Million | 566.09 Million | 7.12 Million | -39.12 Million |
| Investment purchases | -300 Thousand | -12.4 Million | -1.71 Billion | -1.51 Billion | -60 Million | - |
| Sales/Maturities of investments | 3.36 Million | 51 Million | 1.52 Billion | 1.49 Billion | 1.55 Million | 86.11 Million |
| Other Investing Activities | 186.04 Million | 549.87 Thousand | 873.81 Thousand | 1.71 Million | 5.53 Million | 231.45 Thousand |
| Financing Cash Flow | -908.17 Million | -189.42 Million | -910.57 Million | -587.15 Million | -982.76 Million | -96.97 Million |
| Debt repayment | -606.19 Million | -2.01 Billion | -4.25 Billion | -3.56 Billion | -4.54 Billion | -3.8 Billion |
| Dividends payments | -116.63 Million | -116.63 Million | -230.33 Million | -197.56 Million | -206.94 Million | -252.54 Million |
| Common Stock Repurchased | -141.4 Million | - | - | -86.18 Million | -369.19 Million | -300 Million |
| Common Stock Issuance | - | - | - | 86.18 Million | 369.19 Million | - |
| Other Financing Activities | -43.95 Million | 1.99 Billion | 3.57 Billion | 3.17 Billion | 3.76 Billion | 3.96 Billion |
| Accounts receivables | 103.28 Million | 94.98 Million | -609.76 Million | 348.14 Million | 198.38 Million | -647.04 Million |
| Accounts payables | -33.64 Million | -108.31 Million | 372.57 Million | -430.64 Million | -87.24 Million | 101.74 Million |
| Inventory | 24.41 Million | -97 Million | -92.31 Million | 150.92 Million | 50.14 Million | -344.42 Million |
| Other working capital | -44.68 Million | -6.78 Million | -9.1 Million | 6.41 Million | -9.58 Million | -553.11 Million |
| Cash at beginning of period | 899.18 Million | 513.65 Million | 1.71 Billion | 1.14 Billion | 1.49 Billion | 2.01 Billion |
| Cash at end of period | 805.98 Million | 797.01 Million | 513.65 Million | 1.71 Billion | 1.14 Billion | 1.49 Billion |
| Capital Expenditure | -135.78 Million | -158.78 Million | -253.76 Million | -138.08 Million | -207.53 Million | -263.51 Million |
| Effect of forex changes on cash | 1931.07 | 899.35 | -1117.47 | 2.26 Million | 285.32 Thousand | 12.69 Million |
| Net cash flow / Change in cash | -93.19 Million | 283.35 Million | -1.19 Billion | 565.21 Million | -349.47 Million | -519.13 Million |
| Free Cash Flow | 666.27 Million | 432.01 Million | 204.2 Million | 604.02 Million | 678.79 Million | -482.08 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 61.71 Million | 56.05 Million | 58.82 Million | 287.23 Million | 40.65 Million | 90.55 Million |
| Depreciation & Amortization | - | 59.42 Million | 59.42 Million | 255.82 Million | 63.83 Million | -115.74 Million |
| Deferred income taxes | - | - | - | -11.04 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 98.89 Million | - | 94.05 Million | 127.7 Million | 99.53 Million |
| Other non-cash items | 188.25 Million | 182 Million | -56.27 Million | 593.57 Million | 95.85 Million | 473.38 Million |
| Investing Cash Flow | -33.94 Million | 1.55 Million | -61.05 Million | 39.8 Million | 83.88 Million | -26.79 Million |
| Investments in PPE | -33.99 Million | -1 Million | -61.06 Million | -135.78 Million | -52.93 Million | -28.07 Million |
| Acquisitions | 58.99 Thousand | 22 Thousand | 4930.00 | 172.51 Million | 133.75 Million | 1.51 Million |
| Investment purchases | - | - | - | -300 Thousand | -300 Thousand | -1.51 Million |
| Sales/Maturities of investments | - | 2.53 Million | 10.4 Thousand | 3.36 Million | 3.36 Million | 1.24 Million |
| Other Investing Activities | - | 2.55 Million | 15.33 Thousand | 186.04 Million | 147.98 Million | 40.34 Thousand |
| Financing Cash Flow | -218.73 Million | -13.1 Million | -128.28 Million | -908.17 Million | -405.64 Million | -252.99 Million |
| Debt repayment | -180 Million | -121 Million | -89 Million | -606.19 Million | -333.5 Million | -558 Million |
| Dividends payments | - | -114.39 Million | -4.39 Million | -116.63 Million | -116.63 Million | -9.73 Million |
| Common Stock Repurchased | 70.62 Million | -70.62 Million | - | -141.4 Million | -141.4 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -109.36 Million | 20.2 Million | -39.28 Million | -43.95 Million | 185.89 Million | 314.73 Million |
| Accounts receivables | - | 2.01 Million | - | 103.28 Million | 103.28 Million | 123.6 Million |
| Accounts payables | - | - | - | -33.64 Million | - | - |
| Inventory | - | 96.87 Million | - | 24.41 Million | 24.41 Million | -24.07 Million |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 729.98 Million | 543.9 Million | 805.98 Million | 899.18 Million | 1.05 Billion | 711.83 Million |
| Cash at end of period | 752.33 Million | 710.98 Million | 613.96 Million | 805.98 Million | 805.98 Million | 979.77 Million |
| Capital Expenditure | -33.99 Million | -1 Million | -61.06 Million | -135.78 Million | -52.93 Million | -28.07 Million |
| Effect of forex changes on cash | - | -625.58 | 502.35 | 1931.07 | 1214.05 | -1293.28 |
| Net cash flow / Change in cash | 22.34 Million | 167.08 Million | -192.01 Million | -93.19 Million | -252.42 Million | 267.93 Million |
| Free Cash Flow | 215.96 Million | 177.63 Million | -58.52 Million | 666.27 Million | 19.73 Million | 519.65 Million |
605599
IDGAF
600171
300683
QIIWI
STAR-B